REG - Oxford Biomedica PLC - PDMR Dealings / Market Share Purchase

Oxford BioMedicaAnnouncement

27/04/2022 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220427:nRSa5579Ja&default-theme=true

RNS Number : 5579J  Oxford Biomedica PLC  27 April 2022

 

 

PDMR Dealings / Market Share Purchase

 

Oxford, UK - 27 April 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a leading gene and cell therapy group, today
announces that Nick Page, Chief Operations Officer of the Group, has purchased
18,243 ordinary shares of 50p each ("Ordinary Shares") in the Company on 27
April 2022 on the London Stock Exchange at a price of 545.3p. Following this
purchase Nick Page holds 18,243 shares representing 0.019% of the Company.

 

The below notification, made in accordance with the requirements of the EU
Market Abuse Regulation, gives further detail of the number of Ordinary Shares
purchased.

 

  1.   Details of the person discharging material responsibilities/person
       closely                 associated

  a.   Name                                                                         Nick Page

  2.   Reason for the notification

  a.   Position/status                                                              Chief Operations officer
  b.   Initial notification /amendment                                              Initial notification

 3.    Details of the issuer, emission allowance, market participant, auction
       platform, auctioneer or auction monitor

  a.   Name                                                                         Oxford Biomedica plc

  b.   Legal Entity Identifier                                                      213800S1GVQNXQ15K851

 4.    Details of the transaction(s); section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted

  a.   Description of the financial instrument, type of instrument identification   Oxford Biomedica plc Ordinary Shares of 50p each
       code

                                                                                    GB00BDFBVT43

 b.    Nature of the transaction                                                    Purchase of ordinary shares

 c.    Currency                                                                     GBP - British Pound

 d.    Price(s) and volume(s)

                                                                                   Price(s)                    Volume(s)

       £5.45                                                                                                   18,243

 e.    Aggregated information

       ·      Aggregated volume                                                     18,243

       ·      Price

       ·      Aggregated total                                                      £5.452762

                                                                                    £99,474.74

 f.    Date of the transaction                                                      2022-04-27

 g.    Place of the transaction                                                     London Stock Exchange, Main Market (XLON)

 

 

 

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform,
which the Group leverages to develop product candidates in-house, before
seeking partners to take the products into clinical trials.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica
Solutions, a new US based subsidiary AAV manufacturing and innovation
business, based near Boston, US.

 

Oxford Biomedica employs more than 940 people. Further information is
available at www.oxb.com.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHPPUBUCUPPGGM